Kymera's CEO Sold $6 Million in Stock After a 170% Run This execution under a pre-scheduled Rule 10b5-1 plan follows 172% one-year stock surge.
Why Kymera Therapeutics Stock Popped This Week It's getting quite the head start on an important clinical trial.
Kymera Therapeutics Stays on Track With KT-621 Trials, Teases IRF5 Data Kymera Therapeutics (
NASDAQ:KYMR ) executives said the company remains on track with key clinical timelines for its lead degrader programs, including KT-621 in atopic dermatitis and asthma, while preparing to share additional data from its IRF5 program later this year.
Speaking at an RBC Capital Mar
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology.
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO Veradermics develops novel dermatology treatments, targeting both adult and pediatric markets with a research-driven approach.
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway-driven cancers, addressing hard-to-treat tumor types.
Nextech Trims Kymera at a Recent High — think Foolishly before acting. Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline.
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology.
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing This clinical-stage biotech develops precision oncology therapies and diagnostics targeting unmet needs in breast and ovarian cancer.
Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing This clinical-stage biotech develops small-molecule therapies for liver and metabolic diseases, targeting unmet needs in NASH and obesity.
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated oncology pipeline.
Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position Structure Therapeutics develops oral drugs for chronic diseases, with lead assets targeting diabetes, obesity, and cardiovascular care.
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of clinical-stage candidates.
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction Disc Medicine develops therapies for rare blood disorders, leveraging clinical-stage biotech expertise in red blood cell biology.
Kymera Stock Up 130% as $135 Million Buy Boosts Immunology Bet Kymera Therapeutics develops targeted protein degradation therapies for immunology, oncology, and fibrosis using proprietary technology.
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.
Streaming Wars Go Hostile Just as Wall Street Braces for the Fed Stocks slipped from record levels on Monday as investors shifted into “wait-and-see” mode ahead of Wednesday’s Fed decision. At the same time, Hollywood turned into a live-fire M&A battlefield, with Paramount Skydance crashing Netflix’s party for Warner Bros. Discovery and IBM writing a big AI-data check for Confluent.
